Gossamer Bio a new outperform at Oppenheimer on seralutinib for PAH
George Clerk Oppenheimer launched Gossamer Bio into an outperformance expressing optimism about seralutinib, an inhaled tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The company has a price…
